ATE462441T1 - Saposin c und rezeptoren als ziele für die behandlung von gutartigen und bösartigen erkrankungen - Google Patents

Saposin c und rezeptoren als ziele für die behandlung von gutartigen und bösartigen erkrankungen

Info

Publication number: ATE462441T1
Authority: AT; Austria
Prior art keywords: saposin; cells; prostate; cancer cells; cell
Prior art date: 2002-12-20

Application number

AT03814232T

Other languages

English (en)

Inventor

Shahriar Koochekpour

Olivier Sartor

Original Assignee

Univ Louisiana State

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2002-12-20

Filing date

2003-12-18

Publication date

2010-04-15

2003-12-18 Application filed by Univ Louisiana State filed Critical Univ Louisiana State

2010-04-15 Application granted granted Critical

2010-04-15 Publication of ATE462441T1 publication Critical patent/ATE462441T1/de

Links

102000017852 Saposin Human genes 0.000 title abstract 9
108050007079 Saposin Proteins 0.000 title abstract 9
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title abstract 2
201000010099 disease Diseases 0.000 title 1
210000004027 cell Anatomy 0.000 abstract 7
206010060862 Prostate cancer Diseases 0.000 abstract 4
208000000236 Prostatic Neoplasms Diseases 0.000 abstract 4
206010028980 Neoplasm Diseases 0.000 abstract 3
230000004709 cell invasion Effects 0.000 abstract 3
210000000481 breast Anatomy 0.000 abstract 2
201000011510 cancer Diseases 0.000 abstract 2
230000012292 cell migration Effects 0.000 abstract 2
230000004663 cell proliferation Effects 0.000 abstract 2
150000001875 compounds Chemical class 0.000 abstract 2
210000004072 lung Anatomy 0.000 abstract 2
210000002307 prostate Anatomy 0.000 abstract 2
210000005267 prostate cell Anatomy 0.000 abstract 2
201000001320 Atherosclerosis Diseases 0.000 abstract 1
206010004446 Benign prostatic hyperplasia Diseases 0.000 abstract 1
206010006187 Breast cancer Diseases 0.000 abstract 1
208000026310 Breast neoplasm Diseases 0.000 abstract 1
206010009944 Colon cancer Diseases 0.000 abstract 1
206010058467 Lung neoplasm malignant Diseases 0.000 abstract 1
208000008636 Neoplastic Processes Diseases 0.000 abstract 1
102100036197 Prosaposin Human genes 0.000 abstract 1
208000004403 Prostatic Hyperplasia Diseases 0.000 abstract 1
108010084592 Saporins Proteins 0.000 abstract 1
101710145697 Saposin-C Proteins 0.000 abstract 1
102000003990 Urokinase-type plasminogen activator Human genes 0.000 abstract 1
108090000435 Urokinase-type plasminogen activator Proteins 0.000 abstract 1
239000003098 androgen Substances 0.000 abstract 1
230000010261 cell growth Effects 0.000 abstract 1
210000001072 colon Anatomy 0.000 abstract 1
208000029742 colonic neoplasm Diseases 0.000 abstract 1
208000035475 disorder Diseases 0.000 abstract 1
230000000694 effects Effects 0.000 abstract 1
230000012010 growth Effects 0.000 abstract 1
201000005202 lung cancer Diseases 0.000 abstract 1
208000020816 lung neoplasm Diseases 0.000 abstract 1
230000001404 mediated effect Effects 0.000 abstract 1
108090000765 processed proteins & peptides Proteins 0.000 abstract 1
230000035755 proliferation Effects 0.000 abstract 1
230000001737 promoting effect Effects 0.000 abstract 1
102000004169 proteins and genes Human genes 0.000 abstract 1
108090000623 proteins and genes Proteins 0.000 abstract 1
208000037803 restenosis Diseases 0.000 abstract 1
210000002536 stromal cell Anatomy 0.000 abstract 1
230000004083 survival effect Effects 0.000 abstract 1
239000003053 toxin Substances 0.000 abstract 1
231100000765 toxin Toxicity 0.000 abstract 1
230000001228 trophic effect Effects 0.000 abstract 1
230000004614 tumor growth Effects 0.000 abstract 1
230000002792 vascular Effects 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/415—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from plants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif

Landscapes

Chemical & Material Sciences (AREA)
Health & Medical Sciences (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Molecular Biology (AREA)
Biochemistry (AREA)
Biophysics (AREA)
General Health & Medical Sciences (AREA)
Genetics & Genomics (AREA)
Medicinal Chemistry (AREA)
Gastroenterology & Hepatology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Toxicology (AREA)
Botany (AREA)
Zoology (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines Containing Plant Substances (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Peptides Or Proteins (AREA)
Coloring Foods And Improving Nutritive Qualities (AREA)
External Artificial Organs (AREA)

AT03814232T 2002-12-20 2003-12-18 Saposin c und rezeptoren als ziele für die behandlung von gutartigen und bösartigen erkrankungen ATE462441T1 (de)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US10/324,993 US7166691B2 (en)	2002-12-20	2002-12-20	Saposin C and receptors as targets for treatment of benign and malignant disorders
PCT/US2003/040648 WO2004058165A2 (en)	2002-12-20	2003-12-18	Saposing c and receptors as targets for treatment of benign and malignant disorders

Publications (1)

Publication Number	Publication Date
ATE462441T1 true ATE462441T1 (de)	2010-04-15

Family

ID=32593623

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT03814232T ATE462441T1 (de)	2002-12-20	2003-12-18	Saposin c und rezeptoren als ziele für die behandlung von gutartigen und bösartigen erkrankungen

Country Status (8)

Country	Link
US (1)	US7166691B2 (de)
EP (1)	EP1578436B1 (de)
AT (1)	ATE462441T1 (de)
AU (1)	AU2003301135B2 (de)
CA (1)	CA2510313C (de)
DE (1)	DE60331951D1 (de)
ES (1)	ES2343247T3 (de)
WO (1)	WO2004058165A2 (de)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US7834147B2 (en)	2003-04-28	2010-11-16	Childrens Hospital Medical Center	Saposin C-DOPS: a novel anti-tumor agent
CA3056116A1 (en)	2007-06-22	2008-12-31	Randolph Watnick	Methods and uses thereof of prosaposin
GB0718045D0 (en) *	2007-09-14	2007-10-24	Peptcell Ltd	Pharmaceutical compound
CN102264349A (zh) *	2008-11-07	2011-11-30	儿童医院医疗中心	用于跨膜药物递送系统的鞘脂激活蛋白c以及相关蛋白和肽促融合性质
EP3560509B1 (de) *	2011-12-22	2024-01-31	Children's Medical Center Corporation	Aus saposin-a gewonnene peptide und verwendungen davon
CN105358708B (zh)	2013-03-14	2024-07-16	儿童医学中心公司	Cd36鉴定癌症对象以用于治疗的用途
LT4095130T (lt)	2013-10-18	2024-04-25	Novartis Ag	Žymėti prostatos specifinio membranos antigeno (psma) inhibitoriai, jų naudojimas kaip vizualizavimo medžiagų ir farmacinių medžiagų prostatos vėžiui gydyti
JP6727129B2 (ja)	2014-03-26	2020-07-22	ザチルドレンズメディカルセンターコーポレーション	環状プロサポシンペプチドおよびその使用
BR112018076306A2 (pt)	2016-06-17	2019-03-26	Magenta Therapeutics, Inc.	composições e métodos para a supressão de células cd117+

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6326467B1 (en) *	1989-02-23	2001-12-04	Colorado State University Research Foundation	Hormone-recombinant toxin compounds and methods for using same
US5576288A (en) *	1989-04-27	1996-11-19	The Salk Institute For Biological Studies	Fibroblast growth factor conjugates
US5191067A (en) *	1989-04-27	1993-03-02	The Salk Institute For Biological Studies	Fibroblast growth factor conjugates
US5478804A (en) *	1990-09-19	1995-12-26	The Salk Institute For Biological Studies	Treatment of tumorigenic pathophysiological conditions with FGF-cytoxic conjugates
US5571787A (en) *	1993-07-30	1996-11-05	Myelos Corporation	Prosaposin as a neurotrophic factor
US5700909A (en) *	1993-07-30	1997-12-23	The Regents Of The University Of California	Prosaposin and cytokine-derived peptides
US6348194B1 (en) *	1995-11-13	2002-02-19	Ixsys Incorporated	Tumor specific internalizing antigens and methods for targeting therapeutic agents
US6271196B1 (en) *	1996-03-05	2001-08-07	Regents Of The University Of Ca	Methods of alleviating neuropathic pain using prosaposin-derived peptides

2002
- 2002-12-20 US US10/324,993 patent/US7166691B2/en not_active Expired - Fee Related
2003
- 2003-12-18 WO PCT/US2003/040648 patent/WO2004058165A2/en not_active Ceased
- 2003-12-18 ES ES03814232T patent/ES2343247T3/es not_active Expired - Lifetime
- 2003-12-18 AT AT03814232T patent/ATE462441T1/de not_active IP Right Cessation
- 2003-12-18 AU AU2003301135A patent/AU2003301135B2/en not_active Ceased
- 2003-12-18 EP EP03814232A patent/EP1578436B1/de not_active Expired - Lifetime
- 2003-12-18 DE DE60331951T patent/DE60331951D1/de not_active Expired - Lifetime
- 2003-12-18 CA CA2510313A patent/CA2510313C/en not_active Expired - Fee Related

Also Published As

Publication number	Publication date
DE60331951D1 (de)	2010-05-12
WO2004058165A3 (en)	2005-03-24
EP1578436A2 (de)	2005-09-28
CA2510313C (en)	2011-09-27
US20040120961A1 (en)	2004-06-24
US7166691B2 (en)	2007-01-23
CA2510313A1 (en)	2004-07-15
EP1578436B1 (de)	2010-03-31
EP1578436A4 (de)	2008-02-27
WO2004058165A2 (en)	2004-07-15
ES2343247T3 (es)	2010-07-27
AU2003301135B2 (en)	2008-06-19
AU2003301135A1 (en)	2004-07-22

Similar Documents

Publication	Publication Date	Title
Jabłońska-Trypuć et al.	2016	Matrix metalloproteinases (MMPs), the main extracellular matrix (ECM) enzymes in collagen degradation, as a target for anticancer drugs
Brennen et al.	2012	Rationale behind targeting fibroblast activation protein–expressing carcinoma-associated fibroblasts as a novel chemotherapeutic strategy
Edelweiss et al.	2008	Barnase as a new therapeutic agent triggering apoptosis in human cancer cells
ATE462441T1 (de)	2010-04-15	Saposin c und rezeptoren als ziele für die behandlung von gutartigen und bösartigen erkrankungen
YU54202A (sh)	2006-01-16	Jedinjenja indazola, farmaceutske smeše i postupci za stimulisanje i inhibiranje ćelijske proliferacije
SE8900247D0 (sv)	1989-01-24	Amphiregulin: a novel bifunctional growth modulating glycoprotein
MY137656A (en)	2009-02-27	Tyrosine kinase inhibitors
RU2008144291A (ru)	2010-05-20	Нацеленные связывающие средства, направленные на upar, и их применения
NO990086D0 (no)	1999-01-08	Avkortete, oppl÷selige tumornekrosefaktorreseptorer av type I og type II
ZA202310280B (en)	2024-06-26	Antibody-drug conjugates comprising humanized antibodies targeting urokinase type plasminogen activator receptor associated protein (uparap)
WO2007070372A3 (en)	2008-07-10	Compositions and methods for inhibiting cellular proliferation
EA200500870A1 (ru)	2006-04-28	Пептиды, которые нацелены на опухоль и эндотелиальные клетки, композиции и их применения
MX2025005779A (es)	2025-07-01	Conjugado de anticuerpo-farmaco, metodo de preparacion y uso del mismo
ATE488529T1 (de)	2010-12-15	Zusammensetzungen und verfahren zur behandlung von tumoren
DK1007095T3 (da)	2005-01-24	Kimære toksiner omfattende GnRH til målrettet terapi
AU2002350623A1 (en)	2003-05-06	Targeted thrombosis by tissue factor polypeptides
DE69936451D1 (de)	2007-08-16	Verwendung von anti-prolaktin agentien zur behandlung von krebs
David et al.	2025	Cathepsins: Novel opportunities for antibody therapeutics in cancer
ATE454400T1 (de)	2010-01-15	Auf rtvp basierende zusammensetzungen und verfahren zur behandlung von prostata-krebs
WO2003026580A3 (en)	2003-12-11	Interactive therapeutic enclosures
Ribatti	2025	Mast cell proteases and metastasis
MX2023006148A (es)	2023-08-07	Polipeptidos que eligen como objetivo a dr4 y/o dr5 y composiciones y metodos relacionados.
Wang et al.	2004	Antitumor effects of the molecule-downsized immunoconjugate composed of lidamycin and Fab’fragment of monoclonal antibody directed against type IV collagenase
ATE373661T1 (de)	2007-10-15	1.3.4-triaza-phenalen- und 1,3,4,6- tetraazaphenalen-derivative
Lee et al.	2006	Hepatocyte growth factor/c-met signaling in regulating urokinase plasminogen activator in human stomach cancer: A potential therapeutic target for human stomach cancer

Legal Events

Date	Code	Title	Description
2010-09-15	RER	Ceased as to paragraph 5 lit. 3 law introducing patent treaties